Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Venn Life Sciences Holdings

Market Cap 54.27M 72.7M 62.72M 57.66M 102M 6.86B 103M 683M 266M 3.37B 273M 267M 11.65B P/E 2026 *
-15.9x
P/E 2027 * -79x
Enterprise Value 45.66M 61.17M 52.77M 48.52M 85.81M 5.77B 86.53M 575M 224M 2.83B 230M 225M 9.8B EV / Sales 2026 *
0.91x
EV / Sales 2027 * 0.81x
Free-Float
96.84%
Yield 2026 *
0.84%
Yield 2027 * 1.05%

Last Transcript: Venn Life Sciences Holdings

Manager TitleAgeSince
Chief Executive Officer 57 2022-02-23
Corporate Officer/Principal 39 2017-06-30
Director of Finance/CFO 63 2022-10-17
Director TitleAgeSince
Chairman 65 2025-06-04
Director/Board Member 57 2021-10-12
Director/Board Member 63 2022-10-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 72.84M
-0.22%-1.14%-11.88%-13.09% 43.51B
+0.76%+9.42%+303.09%+540.82% 33.29B
-4.74%-6.31%+10.75%-20.99% 29.9B
-0.47%-0.35%+3.38%+31.20% 29.34B
+0.06%+4.36%+13.31%+21.11% 25.42B
-0.02%+10.18% - - 14.36B
-0.98%-1.86%+53.43%+106.06% 13.18B
-0.29%-4.40%+3.13%+1.69% 12.72B
+1.67%+1.35%+105.56%+81.16% 12.08B
Average -0.42%+1.60%+60.10%+93.50% 23.76B
Weighted average by Cap. -0.63%+1.76%+61.93%+103.58%

Financials

2026 *2027 *
Net sales 50.38M 67.48M 58.21M 53.52M 94.66M 6.37B 95.46M 634M 247M 3.13B 253M 248M 10.81B 54.95M 73.6M 63.5M 58.38M 103M 6.95B 104M 692M 269M 3.41B 276M 270M 11.79B
Net income -3.49M -4.68M -4.04M -3.71M -6.56M -441M -6.62M -43.96M -17.12M -217M -17.55M -17.18M -749M -1.14M -1.53M -1.32M -1.22M -2.15M -145M -2.17M -14.4M -5.61M -70.98M -5.75M -5.63M -246M
Net Debt -8.61M -11.53M -9.95M -9.15M -16.18M -1.09B -16.31M -108M -42.2M -534M -43.29M -42.36M -1.85B -9.64M -12.92M -11.15M -10.25M -18.12M -1.22B -18.28M -121M -47.28M -598M -48.49M -47.45M -2.07B
Logo Venn Life Sciences Holdings
hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BBB
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!